Annexon, Inc. (ANNX)

NMS – Real vaqt narxi. Valyuta: USD

5.48

+0.33 (6.41%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

5.60

+0.12 (2.19%)

Bozordan keyin: Jun 26, 2026, 7:06 PM EDT

16.06.2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

09.06.2026

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

09.06.2026

Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead

Annexon NASDAQ: ANNX executives used a Goldman Sachs Healthcare Conference session to outline the company's upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular degeneration.

04.06.2026

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon NASDAQ: ANNX executives outlined a series of expected clinical and regulatory updates across the company's complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease.

27.05.2026

Annexon to Participate in Upcoming June Investor Conferences

BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences:

18.05.2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

14.05.2026

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference

Annexon NASDAQ: ANNX President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome.

Videolar

No Data

There is no data to display

Press-relizlar

16.06.2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18.05.2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

11.05.2026

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl.

07.05.2026

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA

Annexon, Inc. (ANNX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Annexon, Inc. (ANNX)

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon to Participate in Upcoming June Investor Conferences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference

Videolar

No Data

Press-relizlar

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon to Participate in Upcoming June Investor Conferences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference

Videolar

No Data

Press-relizlar

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Search stocks

Annexon, Inc. (ANNX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Annexon, Inc. (ANNX)

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon to Participate in Upcoming June Investor Conferences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference

Videolar

No Data

Press-relizlar

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon to Participate in Upcoming June Investor Conferences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference

Videolar

No Data

Press-relizlar

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones